On Friday, our team joined a nationwide movement at the #StandUpForScience2025 Rally in San Francisco to celebrate the impact of science and research on society. It was inspiring to see so many people come together in support of discovery, progress, and innovation. Thank you to everyone who participated, engaged, and showed their support. Let’s continue to champion the role of research and evidence-based decision-making in shaping a better world. #ScienceMatters #ResearchForAll #StandUpForScience
Lycia Therapeutics
生物技术研究
South San Francisco,California 5,205 位关注者
Building the leading extracellular protein degradation company
关于我们
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
- 网站
-
https://lyciatx.com/
Lycia Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco,California
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
E Jamie Ct
US,California,South San Francisco,94080
Lycia Therapeutics员工
动态
-
Science is at the heart of innovation, discovery, and progress. It improves lives, advances healthcare, and strengthens our communities. That’s why we’re coming together to #StandUpForScience on March 7 in San Francisco. This nationwide movement is an opportunity for scientists, healthcare professionals, advocates, and supporters to show their commitment to the value of research and evidence-based decision-making. We’re especially excited that Lycia’s founder, Nobel Laureate Carolyn Bertozzi, will be speaking at the rally, lending her voice to this critical cause. We encourage everyone who believes in the power of science to join us. Let’s stand together in support of innovation and discovery. #ScienceMatters #ResearchForAll #StandUpForScience2025
-
-
Science is at the heart of innovation, discovery, and progress. It improves lives, advances healthcare, and strengthens our communities. That’s why we’re coming together to #StandUpForScience on March 7 in San Francisco. This nationwide movement is an opportunity for scientists, healthcare professionals, advocates, and supporters to show their commitment to the value of research and evidence-based decision-making. We’re especially excited that Lycia’s founder, Nobel Laureate Carolyn Bertozzi, will be speaking at the rally, lending her voice to this critical cause. We encourage everyone who believes in the power of science to join us. Let’s stand together in support of innovation and discovery. #ScienceMatters #ResearchForAll #StandUpForScience2025
-
-
A huge thank you to all the industry leaders, researchers, and clinicians who took the time to connect with us at the 2025 American Academy of Allergy, Asthma and Immunology - AAAAI congress in San Diego! It was inspiring to engage in meaningful discussions about the future of allergy and immunology research and share how Lycia’s #LYTAC platform is unlocking new possibilities in targeted protein degradation. We’re excited about the collaborations and insights gained at the meeting and look forward to continuing the conversation. Until next time!
-
-
Lycia Therapeutics’ leadership team will be attending the 2025 American Academy of Allergy, Asthma and Immunology - AAAAI/WAO Joint Congress in San Diego, California, from February 28 – March 3. We look forward to engaging with industry leaders, researchers, and clinicians to discuss the latest advancements in allergy and immunology R&D and share how Lycia’s innovative LYTAC platform is shaping the future of targeted protein degradation. If you’ll be at #AAAAI2025, let’s connect!
-
-
Science needs women. On International Day of Women and Girls in Science, we recognize the brilliant minds, bold ideas, and groundbreaking discoveries driven by women in STEM. But celebrating isn’t enough—we need to open more doors, break more barriers, and create more opportunities for the next generation. At Lycia, we are guided by the ideals of our founder, Carolyn Bertozzi, whose visionary leadership continues to inspire women in science. In that spirit, we celebrate outstanding contributions of all Lycian scientists to our programs. Let’s honor these women—and all those who came before them—by ensuring that every girl with a passion for science has the opportunity to turn curiosity into discovery. #WomenInScience #WomenInSTEM #FutureInnovators #BreakingBarriers
-
-
Science needs women. On International Day of Women and Girls in Science, we recognize the brilliant minds, bold ideas, and groundbreaking discoveries driven by women in STEM. But celebrating isn’t enough—we need to open more doors, break more barriers, and create more opportunities for the next generation. At Lycia, we are guided by the ideals of our founder, Carolyn Bertozzi, whose visionary leadership continues to inspire women in science. In that spirit, we celebrate outstanding contributions of all Lycian scientists to our programs. Let’s honor these women—and all those who came before them—by ensuring that every girl with a passion for science has the opportunity to turn curiosity into discovery. #WomenInScience #WomenInSTEM #FutureInnovators #BreakingBarriers
-
-
We’re excited to welcome Chin Lee, MD, MPH, as our Chief Medical Officer? to help drive our next phase of growth! Dr. Lee brings over 20 years of clinical development experience in autoimmune and inflammatory diseases across multiple therapeutic areas, including allergy, rheumatology, dermatology, and gastroenterology. Today, we also unveiled our lead pipeline programs. We are focused on autoimmune and inflammatory diseases, including Graves’ disease and food allergy — conditions with high unmet need where existing treatments often fall short. Lycia’s #LYTAC platform, a new approach to targeted protein degradation, is powering our pipeline of best-in-class therapies that eliminate disease-driving extracellular and membrane-bound proteins: ? LCA-0061 (CataLYTAC? degrader) – Engineered to rapidly degrade IgE, a key factor in food allergy, allergic asthma, and chronic spontaneous urticaria, with the potential to offer a more effective and sustained treatment. ? LCA-0321 (LYTAC degrader) – Designed to selectively eliminate the autoantibodies that fuel Graves’ disease without broad immunosuppression. With Dr. Lee joining our growing team of talented people at Lycia, we will be closer to delivering much-needed therapies that eliminate key drivers of disease. Welcome to the team, Dr. Lee! Read the full announcement here: https://lnkd.in/gNn5GV57
-
-
At Lycia Therapeutics, we believe in shaping the future by inspiring the next generation of innovators. Last week, we proudly partnered with Biocom California's Generation STEAM to host a day of giving back to our community. We welcomed over 30 students from the City of Hayward’s Tennyson High School's Biomedical CTE Program for a day of exploration and learning at our facilities. The students participated in an engaging career panel, a hands-on science session, and a behind-the-scenes tour of our work in life sciences. Later, our team came together to assemble 209 STEAM education kits, which were donated to students at Martin Elementary School in South San Francisco and our partners at BioLink Depot. These kits are designed to spark curiosity and nurture a love for science, technology, engineering, art, and math in young minds. We are honored to support Generation STEAM’s mission of empowering underserved K-12 students across California. A heartfelt thank you to everyone who made this day possible. Together, we’re inspiring the next generation of STEAM leaders!
-
-
Our groundbreaking research on CataLYTAC technology has just been posted on bioRxiv & medRxiv! ? CataLYTACs represent a major leap in extracellular targeted protein degradation technology, achieving catalytic degradation of circulating targets for enhanced efficiency and durability. ? In non-human primates, CataLYTACs demonstrated deep and?sustained target depletion, outperforming traditional therapies. This proof-of-concept research validates our platform's potential to transform therapies for diseases caused by circulating proteins. ? Learn more about how we're redefining drug development by engineering antibodies into highly efficient, potent and targeted CataLYTACs. ? Read the preprint here: https://bit.ly/4fVB0UF #Biotech #CataLYTAC #Innovation #ProteinDegradation
-